1Dupont D,Moriniere P,Pourchez T,et al.Long-term development of Permacath Quinton catheters used as a vascular access route for extra-renal detoxification.Nephrologie,1994,15(2):105-110.
2Cynamon J,Pierpont CE.Thrombolysis for the treatment of thrombosed hemodialysis access grafts.Rev Cardiovasc Med,2002,3 (Suppl 2):75-82.
1[1]Cynamon J, Pierpont CE. Thrombolysis for the treatment of thrombosed hemodialysis access grafts. Rev Cardiovasc Med, 2002, 3 Suppl 2: S75-82
2[2]Cynamon J, Lakritz PS, Wahl SI, et al. Hemodialysis graft declotting: description of the "lyse and wait" technique. JVIR, 1997, 8: 825-829
3[3]Schon D, Mishler R. Salvage of occluded autologous arteriovenous fistulae. Am J Kidney Dis, 2000, 36(4): 804-810
4[4]Gruber A, Harker LA, Hanson SR, et al. Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates. Circulation, 1991,84(6): 2454-2462
5[5]Sofocleous CT, Cooper SG, Schur I, et al. Retrospective comparison of the amplatz thrombectomy device with modified pulse-spray pharmacomechanical thrombolysis in the treatment of thrombosed hemodialysis access grafts. Radiology, 1999, 213(2): 561-567
6[7]Wall TC, Califf RM, Ellis SG, et al. Lack of impact of early catheterization and fibrin specificity on bleeding complications after thrombolytic therapy. The TAMI Study Group. J Am Coll Cardiol, 1993, 21(3): 597-603
7[8]Ash S, Weng FL, Berns JS. Complications of percutaneous treatment of thrombosed hemodialysis access grafts. Semin Dial, 2003, 16(3): 257-262
8[9]Kalodiki E, Nicolaides AN. Superficial thrombophlebitis and low-molecular-weight heparins. Angiology, 2002, 53(6): 659-663
9Pastan S, Soucie JM, McClellan WM. Vascular access and increased risk of death among hemodialysis patients. Kidney Int, 2002,62(2) :620 - 626.
10No authors Listed. Cause of death. USRDS. United States Renal Data System. Am J Kidney Dis, 1997,30(2 Suppl 1 ) :107- 117.
